TMCnet News

Research and Markets: Myelofibrosis Pipeline Review 2015 - 18 Companies & 23 Drug Profiles
[March 04, 2015]

Research and Markets: Myelofibrosis Pipeline Review 2015 - 18 Companies & 23 Drug Profiles


Research and Markets (http://www.researchandmarkets.com/research/t3lf4s/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strateges to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.



Companies Involved in Therapeutics Development

  • Acceleron Pharma, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • CTI (News - Alert) BioPharma Corp.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Italfarmaco S.p.A.
  • Johnson & Johnson
  • KaloBios Pharmaceuticals, Inc.
  • MEI Pharma, Inc.
  • Nippon Shinyaku Co., Ltd.
  • Novartis AG
  • Onconova Therapeutics, Inc.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Promedior, Inc.
  • Stemline Therapeutics, Inc.
  • Threshold Pharmaceuticals, Inc.

Drug Profiles


  • BMS-911543
  • buparlisib hydrochloride
  • erismodegib
  • evofosfamide
  • givinostat
  • glasdegib
  • imetelstat sodium
  • INCB-39110
  • KB-004
  • LCL-161
  • momelotinib
  • NS-018
  • pacritinib
  • panobinostat
  • peginterferon alfa-2b
  • pomalidomide
  • pracinostat
  • PRM-151
  • rigosertib sodium
  • simtuzumab
  • SL-401
  • Small Molecules to Inhibit JAK for Oncology and Hematological Disorders
  • sotatercept

For more information visit http://www.researchandmarkets.com/research/t3lf4s/myelofibrosis


[ Back To TMCnet.com's Homepage ]